FDA developing new rules for artificial intelligence in medicine
The FDA announced Tuesday that it is developing a framework for regulating artificial intelligence products used in medicine that continually adapt based on new data.
The Food and Drug Administration announced Tuesday that it is developing a framework for regulating artificial intelligence products used in medicine that continually adapt based on new data.
The agency’s outgoing commissioner, Scott Gottlieb, released a white paper that sets forth the broad outlines of the FDA’s proposed approach to establishing greater oversight over this rapidly evolving segment of AI products.
It is the most forceful step the FDA has taken
